US20080299214A1 - Intervertebral Disc Repair, Methods and Devices Therefor - Google Patents
Intervertebral Disc Repair, Methods and Devices Therefor Download PDFInfo
- Publication number
- US20080299214A1 US20080299214A1 US12/058,193 US5819308A US2008299214A1 US 20080299214 A1 US20080299214 A1 US 20080299214A1 US 5819308 A US5819308 A US 5819308A US 2008299214 A1 US2008299214 A1 US 2008299214A1
- Authority
- US
- United States
- Prior art keywords
- chondrocytes
- biocompatible molecule
- composition
- cartilage
- intervertebral disc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000008439 repair process Effects 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims abstract description 23
- 210000000845 cartilage Anatomy 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 37
- 238000002347 injection Methods 0.000 claims description 32
- 239000007924 injection Substances 0.000 claims description 32
- 108010049003 Fibrinogen Proteins 0.000 claims description 24
- 102000008946 Fibrinogen Human genes 0.000 claims description 24
- 108090000190 Thrombin Proteins 0.000 claims description 24
- 229940012952 fibrinogen Drugs 0.000 claims description 24
- 229960004072 thrombin Drugs 0.000 claims description 24
- 108010073385 Fibrin Proteins 0.000 claims description 14
- 102000009123 Fibrin Human genes 0.000 claims description 14
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 14
- 229950003499 fibrin Drugs 0.000 claims description 14
- 210000003035 hyaline cartilage Anatomy 0.000 claims description 9
- 239000000565 sealant Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 6
- 208000018180 degenerative disc disease Diseases 0.000 claims description 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims 3
- 210000001612 chondrocyte Anatomy 0.000 abstract description 179
- 102000000503 Collagen Type II Human genes 0.000 abstract description 35
- 108010041390 Collagen Type II Proteins 0.000 abstract description 35
- 238000000338 in vitro Methods 0.000 abstract description 20
- 230000003412 degenerative effect Effects 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 10
- 229920002674 hyaluronan Polymers 0.000 description 10
- 229960003160 hyaluronic acid Drugs 0.000 description 10
- 238000002513 implantation Methods 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 230000007547 defect Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 229940033618 tisseel Drugs 0.000 description 6
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 5
- 241000282465 Canis Species 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 229960005188 collagen Drugs 0.000 description 5
- 238000002224 dissection Methods 0.000 description 5
- 229940014041 hyaluronate Drugs 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 102000001187 Collagen Type III Human genes 0.000 description 4
- 108010069502 Collagen Type III Proteins 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 210000004705 lumbosacral region Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000004349 growth plate Anatomy 0.000 description 3
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 3
- 210000000867 larynx Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000020307 Spinal disease Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000416098 Heliotropium angiospermum Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 101100326696 Rattus norvegicus Capn8 gene Proteins 0.000 description 1
- 101100495263 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDC24 gene Proteins 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229940081104 fibrinogen / thrombin Drugs 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940043200 pentothal Drugs 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
Definitions
- Intervertebral disc degeneration is a leading cause of pain and disability in the adult population. Approximately 80% of the population experience at least a single episode of significant back pain in their lifetimes. For many individuals, spinal disorders become a lifelong affliction. The morbidity associated with disc degeneration and its spectrum of associated spinal disorders is responsible for significant health care, economic and social costs. Furthermore, changes in disc morphology, such as disc compression associated with aging, can lead to unwanted changes in height or posture. Current treatments for repairing or ameliorating disc degeneration, such as spinal fusion, can be expensive, painful, or lengthy. Alternative treatments are, therefore, needed.
- compositions, methods and devices for repair, replacement and/or supplementation of an intervertebral disc which involve implantation or injection of chondrocytes into a degenerative disc, as well as compositions and methods for providing chondrocytes to a treatment provider.
- a method can comprise implanting, into the intervertebral disc, chondrocytes obtained from a cadaver.
- the cadaver chondrocytes can be from any cartilaginous tissue of the cadaver, provided the chondrocytes express type II collagen.
- the chondrocytes expressing type II collagen can be chondrocytes expressing high molecular weight sulfated proteoglycan (HSPG).
- the chondrocytes can be, for example, hyaline cartilage chondrocytes.
- the chondrocytes can be chondrocytes from one or more intervertebral discs, or the chondrocytes can be non-intervertebral disc chondrocytes.
- Chondrocytes from an intervertebral disc can be chondrocytes from the annulus of a disc, chondrocytes from the nucleus pulposus of a disc, or a combination thereof.
- Non-limiting examples of non-intervertebral disc tissue which can be sources of chondrocytes include cartilage of the nose, ears, trachea and larynx, as well as articular cartilage, costal cartilage, cartilage of an epiphyseal plate, and combinations thereof.
- the chondrocytes can be extracted from a cadaver at any time following death while the chondrocytes remain viable.
- chondrocytes can be extracted from a cadaver up to about fourteen days following death.
- Chondrocytes can be removed from a cadaver from about one hour following death to about fourteen days following death, from greater than 24 hours following death to about thirteen days following death, from about two days following death to about twelve days following death, from about three days following death to about twelve days following death, or from about four days following death to about ten days following death.
- chondrocytes of the present teachings can be chondrocytes extracted from a cadaver of any chronological age at time of death.
- chondrocytes can be extracted from a cadaver which is no older than about 40 years of age at time of death, no older than about 30 years of age at time of death, no older than about 20 years of age at time of death, or no older than about 10 years of age at time of death.
- a donor cadaver need not be a familial member of a recipient, or be otherwise matched immunologically.
- chondrocytes which are extracted from a cadaver can be grown in vitro prior to their implantation or injection into a recipient patient or purveyance to a treatment provider. Growth of chondrocytes in vitro can be used, for example, to increase the number of chondrocytes available for implantation or injection. In non-limiting example, chondrocyte numbers can be increased about two fold or greater, about ten fold or greater, or about twenty fold or greater.
- growing chondrocytes in vitro can comprise placing one or more cartilage tissue pieces removed from a cadaver into a tissue culture or cell culture medium which comprises nutrients, buffers, salts, proteins, vitamins and/or growth factors which promote chondrocyte growth, and incubating the chondrocytes.
- tissue comprising chondrocytes expressing type II collagen can be dissociated into single cells or small groups of cells prior to, or in conjunction with, their introduction into a culture medium.
- in vitro culture of chondrocytes expressing type II collagen can further comprise removing non-chondrocyte cells from a cell- or tissue-culture.
- chondrocytes expressing type II collagen can be comprised by a composition which can be implanted or injected into an intervertebral disc of a patient in need of treatment. Accordingly, in certain embodiments, the present teachings also include compositions comprising cadaver chondrocytes expressing type II collagen for use in implantation or injection into a degenerative intervertebral disc of a patient in need of treatment. In some configurations of these embodiments, the chondrocytes of these compositions can comprise chondrocytes expressing high molecular weight sulfated proteoglycan. In some configurations, a composition comprising chondrocytes expressing type II collagen can further comprise at least one biocompatible molecule.
- biocompatible molecules which can be comprised by a composition of the present teachings include fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid (HA), hydrogel, pegylated hydrogel, chitosan, and combinations thereof.
- the present teachings include methods of forming a composition comprising cadaver chondrocytes.
- a composition formed by these methods can further comprise one or more biocompatible molecules such as those described supra.
- methods of these embodiments can comprise contacting cadaver chondrocytes expressing type II collagen with one or more biocompatible molecules, such as, for example, fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid, hydrogel, pegylated hydrogel, chitosan and combinations thereof.
- the cadaver chondrocytes expressing type II collagen can be, in some configurations, chondrocytes which also express high molecular weight sulfated proteoglycan.
- the chondrocytes can be incubated in vitro in a culture medium prior to the contacting with one or more biocompatible molecules.
- the present teachings include methods of forming a composition comprising cadaver tissue comprising chondrocytes.
- a composition formed by these methods can further comprise one or more biocompatible molecules such as those described supra.
- methods of these embodiments can comprise contacting cadaver tissue comprising chondrocytes expressing type II collagen with one or more biocompatible molecules, such as, for example, fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid, hydrogel, pegylated hydrogel, chitosan and combinations thereof.
- the cadaver chondrocytes expressing type II collagen can be, in some configurations of these embodiments, chondrocytes which also express high molecular weight sulfated proteoglycan.
- cadaver tissue comprising chondrocytes expressing type II collagen can be incubated in vitro in a culture medium prior to the contacting with one or more biocompatible molecules.
- a composition comprising both cadaver chondrocytes expressing type II collagen and one or more biocompatible molecules can be implanted or injected into a degenerative intervertebral disc in a patient in need of treatment.
- implantation or injection of a composition into a disc can comprise implantation or injection of the composition into the annulus of the disc, implantation or injection of the composition into the nucleus pulposus of the disc, implantation or injection of the composition into one or both endplates of the disc, or a combination thereof.
- an aperture can be formed in an annulus of a degenerative disc, and a composition can be introduced into the disc through the aperture.
- surgical techniques such as vertebroplasty and kyphoplasty (Garfin, S. R., et al., Spine 26: 1511-1515, 2001) can be adapted or modified for introducing chondrocytes into a degenerative disc of a patient.
- the present teachings include an apparatus configured for injection of chondrocytes expressing type II collagen to an intervertebral disc of a patient in need of treatment.
- An apparatus configured for injection of chondrocytes expressing type II collagen into an intervertebral disc can comprise chondrocytes expressing type II collagen.
- Chondrocytes of these embodiments can comprise chondrocytes expressing high molecular weight sulfated proteoglycan.
- the apparatus can comprise a composition which comprises the chondrocytes and at least one biocompatible molecule, such as, for example, a biocompatible molecule described supra.
- the chondrocytes expressing type II collagen comprised by the apparatus can be cadaver chondrocytes.
- the cadaver chondrocytes in these embodiments can be intervertebral disc chondrocytes, or non-intervertebral disc chondrocytes, such as those described supra.
- the chondrocytes can be comprised by cadaver tissue.
- An apparatus of the present teachings can further comprise, in some configurations, a syringe, a double syringe, a hollow tube, such as a hollow needle (for example, a Jamshidi needle), a cannula, a catheter, a trocar, a stylet, an obturator, or other instruments, needles or probes for cell or tissue injection, injection, or transfer known to skilled artisans.
- the apparatus can be configured for injection of chondrocytes expressing type II collagen into a nucleus pulposus of an intervertebral disc, an annulus of an intervertebral disc, an endplate of an intervertebral disc or a combination thereof.
- a method of these embodiments can comprise growing cadaver chondrocytes expressing type II collagen in vitro, and delivering the chondrocytes expressing type II collagen to the treatment provider.
- Chondrocytes expressing type II collagen of these embodiments can be, in some configurations, chondrocytes which also express high molecular weight sulfated proteoglycan.
- Methods of these embodiments can further comprise obtaining chondrocytes expressing type II collagen from a cadaver.
- the cadaver chondrocytes expressing type II collagen can be obtained at various time intervals following death of the donor as described supra.
- a donor cadaver of chondrocytes expressing type II collagen can be of an age at time of death as described supra.
- the chondrocytes of these embodiments can be chondrocytes of tissue sources such as those described supra.
- the chondrocytes expressing type II collagen can be purveyed to a treatment provider along with one or more biocompatible molecules, such as those described supra.
- a composition comprising the chondrocytes and one or more biocompatible molecules can be purveyed to a treatment provider.
- the chondrocytes and the one or more biocompatible molecules can be purveyed separately to a treatment provider (either simultaneously or at different times), and the treatment provider can form a composition comprising the chondrocytes and the one or more biocompatible molecules prior to, or in conjunction with, implanting the composition in a patient in need thereof.
- the teachings of the present application also disclose use of cadaver chondrocytes expressing type II collagen for the production of a composition for repairing a degenerative intervertebral disc in a patient in need thereof.
- the chondrocytes can also express high molecular weight sulfated proteoglycan.
- the chondrocytes can be cadaver chondrocytes which are grown in vitro, as described supra.
- a composition of these embodiments can comprise a composition comprising cadaver chondrocytes expressing type II collagen and one or more biocompatible molecules such as those described supra.
- the time interval following death at which the chondrocytes can be removed from a donor can be a time interval as described supra, and the age of a donor cadaver at time of death can be an age as described supra.
- the chondrocytes can include chondrocytes removed from an annulus, chondrocytes removed from a nucleus pulposus, chondrocytes removed from an endplate of an intervertebral disc of a donor cadaver, or a combination thereof.
- the chondrocytes can be chondrocytes removed from other cartilaginous, non-intervertebral disc tissue of a cadaver, such as, for example, hyaline cartilage from the nose, ears, trachea or larynx, as well as articular cartilage, costal cartilage, cartilage of an epiphyseal plate, or combinations thereof.
- FIG. 1 illustrates a normal intervertebral disc (left) and a herniated disc (right),
- FIG. 2 illustrates freshly isolated, juvenile cartilage tissue that has been dissected to small cubes and implanted into a damaged nucleus pulposus region of an intervertebral disc in a composition which can also comprise a biocompatible molecule.
- FIG. 3 illustrates isolated juvenile chondrocytes, freshly isolated or harvested from expanded in vitro cultures which can be implanted into the nucleus pulposus region of an intervertebral disc in a composition which can also comprise a biocompatible molecule.
- FIG. 4 illustrates the gross appearance of an intact unoperated disc harvested from the lumbar region of an adult canine.
- FIG. 5 illustrates an intact nucleus pulposus and the cartilaginous endplate of the disc shown in FIG. 4 .
- FIG. 6 illustrates a section of an intervertebral disk that was treated with human chondrocytes 12 weeks post-injection.
- FIG. 7 represents the highlighted region of FIG. 6 , illustrating the newly synthesized matrix that has replaced the native nucleus 12 weeks after chondrocyte injection.
- FIG. 8 illustrates the gross appearance of discs 12 weeks after chondrocyte injection.
- compositions, methods and devices for repair, replacement and/or supplementation of a degenerative intervertebral disc can involve implantation or injection of chondrocytes into a degenerative disc.
- present teachings also describe methods for providing chondrocytes to a treatment provider.
- degenerative intervertebral disc and “degenerative disc” refer to an intervertebral disc exhibiting disease symptoms, abnormalities or malformations, including but not limited to herniations, disruptions, traumatic injuries, and morphological changes associated with or attributed to aging. Indications of a degenerative intervertebral disc can include, but are not limited to, brittleness of an annulus, tearing of an annulus, and shrinking of a nucleus pulposus.
- the present teaching include methods of repairing a degenerative disc in a human patient in need of treatment.
- Methods of these embodiments can comprise implanting or injecting into the intervertebral disc a composition comprising cadaver chondrocytes.
- cadaver chondrocytes refers to viable chondrocytes originally comprised by a human cadaver, as well as clonal descendants of such chondrocytes, such as chondrocytes grown in vitro.
- Cadaver chondrocytes for use in the various aspects of the present teachings can be obtained from tissues comprising chondrocytes from a cadaver, such as cartilage tissue.
- the cartilage tissue utilized in the present teachings can comprise hyaline cartilage, such as cartilage of the nose, ears, trachea and larynx, articular cartilage, costal cartilage, cartilage of an epiphyseal plate, and combinations thereof.
- the cartilage tissue or chondrocytes can be intervertebral disc cartilage or chondrocytes, or can be cartilage or chondrocytes originating from cartilaginous tissues other than intervertebral disc tissue (herein referred to as “non-intervertebral disc chondrocytes”).
- Viable chondrocytes can be comprised by cartilaginous tissues in a donor cadaver for up to about two weeks after death of the donor.
- the time interval from the time of death of a donor (as determined, for example, by a physician or a coroner) to the time of dissection of cartilage tissue from the donor can be any time from about immediately following a pronouncement of death, to about two weeks following death, such as, without limitation, about one hour, greater than 24 hours, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days about ten days, about eleven days, about twelve days, about thirteen days, or about fourteen days after death.
- a donor cadaver can be of any chronological age at time of death.
- a donor cadaver can be, at time of death, ten years old or younger, twenty years old or younger, thirty years old or younger, or forty years old or younger.
- a donor cadaver need not be a familial member of a recipient, or be otherwise matched immunologically.
- intervertebral cartilage comprises an “immunologically privileged” tissue, so that chondrocytes transplanted to an intervertebral disk are not subject to rejection by the recipient's immune system.
- Cartilage tissue can be removed from a cadaver using any surgical or dissecting techniques and tools known to skilled artisans. Following cartilage removal from a cadaver, the cartilage tissue can be minced, dissociated into single cells or small groups of cells, and/or placed into tissue or cell culture using standard techniques and apparatuses well known to skilled artisans, such as techniques and apparatuses described in the these references. Non-limiting descriptions of methods of cartilage and chondrocyte removal and culture can be found in references such as, for example, Feder, J. et al. in: Tissue Engineering in Musculoskeletal Clinical Practice. American Academy of Orthopaedic Surgeons, 2004; Adkisson, H. D. et al., Clin. Orthop. 391S:S280-S294, 2001; and U.S. Pat. Nos. 6,235,316 and 6,645,316 to Adkisson.
- Cadaver chondrocytes used in the various embodiments of the present teachings are all cadaver chondrocytes which express type II collagen.
- cadaver chondrocytes can comprise chondrocytes expressing other molecular markers such as a high molecular weight sulfated proteoglycan, such as, for example, chondroitin sulfate (Kato, Y., and Gospodarowicz, D., J. Cell Biol. 100: 477-485. 1985). Presence of such markers can be determined using materials and methods well known to skilled artisans, such as, for example, antibody detection and histological staining.
- cadaver chondrocytes or cartilage including cartilage tissue as well as cells, either directly extracted from a cadaver grown in vitro, can be harvested prior to implantation or injection into a patient using cell culture techniques and apparatuses well known to skilled artisans, such as culture methods for neocartilage described in U.S. Pat. Nos. 6,235,316 and 6,645,316 to Adkisson, and other general laboratory manuals on cell culture such as Sambrook, J. et al., Molecular Cloning: a Laboratory Manual (Third Edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; and Spector, D.
- cadaver chondrocytes can be used to increase numbers of chondrocytes which can be implanted into a patient.
- routine laboratory measures known to skilled artisans can be used to detect and remove non-chondrocyte cells from a cell culture, or to test a culture for the presence of biological contaminants such as microorganisms and viruses.
- Primary cultures established starting from cadaver chondrocytes can be grown as long as the chondrocytes remain viable and maintain their normal in vitro histological properties.
- compositions comprising chondrocytes and one or more biocompatible molecules.
- biocompatible molecules can include molecules that enhance survival an/or integration of implanted chondrocytes or cartilaginous tissues into an intervertebral disc.
- examples of such molecules include, without limitation, fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid, hydrogel, pegylated hydrogel, chitosan, and combinations thereof.
- Various commercial formulations comprising such molecules such as, for example, Tisseel® fibrin glue (Baxter Healthcare Corporation, Westlake Village, Calif.) can comprise a composition of the present teachings.
- a composition of the present teachings can comprise, in non-limiting example, chondrocytes grown in culture and Tisseel® fibrin glue.
- cadaver chondrocytes including but not limited to cadaver chondrocytes grown in vitro and cartilage tissue maintained in tissue culture in vitro, can be implanted or injected into an intervertebral disc of a recipient patient using surgical methods and apparatuses known to skilled artisans but adapted for such use.
- chondrocytes or cartilage of the present teachings can be implanted or injected into an annulus of a degenerative intervertebral disc, a nucleus pulposus of an intervertebral disc, one or both endplates of a degenerative intervertebral disc, or a combination thereof.
- an aperture can be introduced into the annulus of an intervertebral disc. The aperture can provide a path for introducing chondrocytes or cartilage tissue into a disc.
- cells or tissue can be placed into an apparatus or device configured for transfer of chondrocytes to or from an intervertebral disc patient, such as, in non-limiting example a biopsy instrument or transplantation instrument comprising a hollow tube or needle, a syringe, a double syringe, a hollow tube, a hollow needle such as a Jamshidi needle, a Cook needle (Cook incorporated, Bloomington, Ind. USA), a cannula, a catheter, a trocar, a stylet, an obturator, or other instruments, needles or probes for cell or tissue injection, injection, or transfer known to skilled artisans.
- a biopsy instrument or transplantation instrument comprising a hollow tube or needle, a syringe, a double syringe, a hollow tube, a hollow needle such as a Jamshidi needle, a Cook needle (Cook incorporated, Bloomington, Ind. USA), a cannula, a catheter, a trocar,
- an apparatus of the present teachings can comprise cadaver chondrocytes as described above, as well as at least one hollow needle or tube through which the chondrocytes can be introduced into an intervertebral disc of a patient.
- the apparatus comprises a composition comprising the chondrocytes as well as at least one biocompatible molecule as described supra.
- These apparatuses can be configured for implanting or injecting chondrocytes into an annulus, a nucleus pulposus, and/or an endplate of a degenerative disc.
- surgical techniques such as vertebroplasty and kyphoplasty (Garfin, S.
- R., et al., Spine 26: 1511-1515, 2001 can be adapted for introduction of chondrocytes into a degenerative disc of a patient.
- an instrument for such as a bone tamp/balloon can be inserted into a degenerative intervertebral disc, and used to create or expand a space or cavity within a degenerative disc, for example in the nucleus pulposus of the disc.
- the balloon can be removed, and chondrocytes expressing type II collagen can then be injected into the expanded space, for example through a catheter.
- the one or more biocompatible molecules may form a chondro-conductive/inductive matrix, carrier, or milieu that comprises, for example, fibrinogen.
- the fibrinogen may be from any suitable source.
- fibrinogen may be derived from blood bank products—either heterologous (pooled or single-donor) or autologous cryoprecipitate or fresh frozen plasma.
- Fibrinogen can also be derived from autologous fresh or platelet-rich plasma, obtained using cell-saver or other techniques.
- U.S. Pat. No. 5,834,420 discloses a method for obtaining fibrinogen.
- the one or more biocompatible molecules may comprise thrombin.
- the thrombin may be from any suitable source.
- thrombin can be isolated by well known means or purchased commercially. See U.S. Pat. No. 4,965,203 and Ralph, J L (Ed), THROMBIN: STRUCTURE AND FUNCTION, Plenum Pub Corp. (1992) for exemplary methods of isolation and/or purification.
- the one or more biocompatible molecules may comprise collagen, hyaluronic acid, fibrinogen, thrombin or any combination thereof.
- the biocompatible molecules in combination may contain equal proportions of each constituent molecule or more of any one or group of the constituents than other(s).
- the collagen, hyaluronic acid, fibrinogen and thrombin may be in any proportion, ranging from one part of one, or one part of a combination of two or more of them compared to the amount of the other(s), up to equal proportions of each constituent.
- the fibrinogen and thrombin components should be kept separate prior to the time of use.
- a common type of applicator that may be used for this purpose consists of a double syringe, joined by a Y-connector where the components mix as they emerge. This type of applicator, used with a blunt cannula, is useful for combining of the collagen, hyaluronic acid, thrombin and the fibrinogen and also useful in the methods of the invention for disposing or transplanting the inventive compositions to a site wherein repair, replacement or supplementation of an intervertebral disc is desired.
- the one or more biocompatible molecules may comprise one or more of collagen, hyaluronic acid, fibrinogen, thrombin, fibrinogen/thrombin (Tisseel), Albumin, in-situ forming PEG hydrogel, fibrin, hyaluronate, fibrin/hyaluronate, collagen/hyaluronate, fibrin/collagen/hyaluronate, PEG/hyaluronate, PEG/collagen, PEG base sealants (CoSeal) or other plasma and protein-based adhesives and/or sealants other natural adhesives and/or sealants and combinations thereof that are biocompatible with regard to the intervertebral nucleus pulposus repair, replacement or supplementation.
- the composition may be disposed in an intervertebral disc in need of repair, replacement or supplementation by being injected through the disc annulus into the center of the damaged disc nucleus.
- additional material may usefully be injected into the track created in the annulus.
- the hyaline cartilage completely fills the nucleus space and fully integrates with the annulus. It is further presumed that the hyaline cartilage comprises of neocartilage or juvenile cartilage and/or cells will also be useful in repairing damaged annulus.
- the present teachings also disclose methods of purveying to a treatment provider chondrocytes for repairing a degenerative intervertebral disc in a patient in need thereof.
- These methods can comprise obtaining chondrocytes from a cadaver, growing the chondrocytes in vitro, then delivering the chondrocytes to the treatment provider.
- the chondrocytes can be obtained from a cadaver using methods described supra, and can be chondrocytes which are adapted for injection into a degenerative intervertebral disc in a patient.
- the adaptation can comprise, in various configurations, expanding the numbers of chondrocytes through growth in vitro.
- Chondrocytes adapted for injection can also comprise, in certain aspects, chondrocytes which can be loosely connected or unattached to each other, and can be chondrocytes not comprised by cartilage tissue.
- the cadaver chondrocytes of these embodiments can be chondrocytes expressing type II collagen, as described supra, and can also be chondrocytes expressing high molecular weight sulfated proteoglycan, also as described supra.
- the chondrocytes can be delivered to a treatment provider, as either a chondrocytes grown in vitro and/or as cartilage tissue pieces as described supra.
- the treatment provider can be, in non-limiting example, a physician such as an orthopedic surgeon, or an agent or employee of the physician or a health care institution such as a hospital or outpatient clinic.
- cadaver chondrocytes can be grown in vitro, and delivered to the treatment provider via a delivery service such as, for example, a courier or an overnight shipper.
- Cadaver chondrocytes and/or cartilage tissue can be prepared for delivering by methods well known to skilled artisans.
- cadaver chondrocytes and/or cartilage tissue can be provided in a composition further comprising at least one biocompatible molecule as described supra.
- the chondrocytes and/or cartilage tissue can be packaged and sent separately from any biomolecule(s).
- the treatment provider can then form the composition by mixing the cells with the one or more biomolecules. In some aspects, the mixing can be done immediately prior to implanting the cells into a recipient patient.
- the following example illustrates transplantation and survival of human chondrocytes transplanted into canine intervertebral disc tissue.
- a pilot animal study was conducted to determine whether human articular chondrocytes survive injection to produce cartilaginous matrices in experimental defects created in the intervertebral disk of adult canines.
- Gross morphologic and histological results obtained from this short-term pilot study (12 weeks) demonstrate that implanted chondrocytes can survive to produce cartilaginous matrices which integrate with surrounding host tissues.
- Surgical Procedure Prior to induction of anesthesia, six adult female dogs were sedated by the attending veterinarian or the veterinary technician/anesthetist using one of the following combinations: Atropine 0.05 mg/kg IM with or without Acepromizine 0.05-0.2 mg/kg IM. An 18 or 20 gauge 11 ⁇ 4 to 2 inch angio-catheter was placed in the cephalic saphenous or auricular vein for venous access. General anesthesia was induced with Pentothal (10-20 mg/kg IV to effect). Animals were intubated with a 7.0 mm-9.0 mm hi-low pressure cuff endotracheal tube. Anesthesia was maintained with isoflurane 2.5-4% in an air-oxygen mixture of 40-60%. The tube was connected to low-pressure continuous suction, and mechanical ventilation was initiated and maintained at 10 ml/kg tidal volume and at a rate of 8-10/minute. Crystalloids were provided at a rate of 7-10 mg/kg/hr.
- Surgical exposure consisted of a 10 cm incision along the abdominal midline, followed by soft tissue dissection to permit transperitoneal exposure of the anterior lumbar spine.
- Human Neocartilage produced at ISTO Technologies according to U.S. Pat. Nos. 6,235,316 and 6,645,764 were enzymatically dissociated in HL-1 Serum-free Medium (Cambrex Bio Science, Walkersville, Md.) containing 60 units/ml CLS4 collagenase (Worthington, Lakewood, N.J.) and 50 units/mL hyaluronidase (Sigma, St. Louis, Mo.).
- the dissociated chondrocytes (derived from the articular cartilage of a six year old individual) were washed in fresh HL-1 medium and briefly exposed to 0.25% EDTA before pelleting at 500 ⁇ g for 7 minutes.
- chondrocyte suspension was prepared using 100 microliters of thrombin solution (Tisseel®, Baxter Healthcare Corporation, Westlake Village, Calif.). This step was completed immediately before mixing with an equivalent volume of the fibrin component (Tisseel®) using the Tisseel® injection device.
- FIGS. 6 and 7 Those discs receiving neocartilage chondrocytes in fibrin glue were observed to contain viable chondrocytes in the disc space, and the injected chondrocytes had synthesized a hyaline matrix enriched in sulfated proteoglycan ( FIGS. 6 and 7 ). Gross macroscopic observation of treated discs show viable cartilaginous tissue occupying the disc space ( FIGS. 8A and B).
- FIG. 4 illustrates the gross appearance of an intact unoperated disc harvested from the lumbar region of an adult canine.
- the disc is split in half to show the morphology of a normal intervertebral disk.
- the annulus fibrosus is the outer fibrocartilaginous structure surrounding the inner jelly-like structure or nucleus pulposus (NP).
- the cartilage endplate covers the surface of the upper and lower vertebral body.
- FIG. 5 illustrates an intact nucleus pulposus and the cartilaginous endplate of the disc shown in FIG. 4 .
- the section was stained with Safranin O to identify sulfated glycosaminoglycans in the NP and in the cartilage end plate. Notice that the NP chondrocytes are significantly larger than chondrocytes of the cartilage endplate and that the endplate contains greater levels of sulfated proteoglycan.
- FIG. 6 illustrates a Safranin O-stained section of an intervertebral disk that was treated with human chondrocytes 12 weeks post-injection.
- the chondrocytes are viable and have synthesized a cartilaginous matrix that is highly enriched in sulfated glycosaminoglycans.
- the injected chondrocytes are much smaller than native NP chondrocytes identified in FIG. 5 .
- the white square identifies the region shown in FIG. 7 .
- FIG. 7 represents the highlighted region of FIG. 6 , illustrating the newly synthesized matrix that has replaced the native nucleus 12 weeks after chondrocyte injection.
- the new matrix appears to be integrated well with the surrounding native tissues.
- Chondrocytes in this newly synthesized matrix (identified with white dotted circles) appear to be randomly distributed and of similar size to chondrocytes of the cartilaginous endplate.
- FIG. 8 is in two parts.
- Panel A illustrates the gross appearance of a disc 12 weeks after chondrocyte injection.
- the native nucleus is no longer present and is replaced by newly synthesized cartilaginous tissue.
- Panel B illustrates the gross appearance of another disc treated in the same manner. The histological features of this disc are shown in FIGS. 6 and 7 .
- the newly synthesized cartilaginous material produced after chondrocyte injection is expected to remodel and take on morphological features that are more characteristic of the native annulus and nucleus within 1 year after treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- This application is a continuing application claiming the benefit of priority from U.S. patent application Ser. No. 11/063,183 filed Feb. 22, 2005, which claims priority from U.S. Provisional Application Ser. No. 60/706,133 filed on Aug. 4, 2005, the disclosures of which are incorporated herein by reference in their entirety.
- Not Applicable.
- Intervertebral disc degeneration is a leading cause of pain and disability in the adult population. Approximately 80% of the population experience at least a single episode of significant back pain in their lifetimes. For many individuals, spinal disorders become a lifelong affliction. The morbidity associated with disc degeneration and its spectrum of associated spinal disorders is responsible for significant health care, economic and social costs. Furthermore, changes in disc morphology, such as disc compression associated with aging, can lead to unwanted changes in height or posture. Current treatments for repairing or ameliorating disc degeneration, such as spinal fusion, can be expensive, painful, or lengthy. Alternative treatments are, therefore, needed.
- In view of the need for disc degeneration treatments, the present inventors have devised compositions, methods and devices for repair, replacement and/or supplementation of an intervertebral disc which involve implantation or injection of chondrocytes into a degenerative disc, as well as compositions and methods for providing chondrocytes to a treatment provider.
- Some embodiments of the present teachings include methods of repairing a degenerative intervertebral disc in a human patient in need of treatment. In these embodiments, a method can comprise implanting, into the intervertebral disc, chondrocytes obtained from a cadaver. The cadaver chondrocytes can be from any cartilaginous tissue of the cadaver, provided the chondrocytes express type II collagen. Furthermore, the chondrocytes expressing type II collagen can be chondrocytes expressing high molecular weight sulfated proteoglycan (HSPG). The chondrocytes can be, for example, hyaline cartilage chondrocytes. In various configurations, the chondrocytes can be chondrocytes from one or more intervertebral discs, or the chondrocytes can be non-intervertebral disc chondrocytes. Chondrocytes from an intervertebral disc can be chondrocytes from the annulus of a disc, chondrocytes from the nucleus pulposus of a disc, or a combination thereof. Non-limiting examples of non-intervertebral disc tissue which can be sources of chondrocytes include cartilage of the nose, ears, trachea and larynx, as well as articular cartilage, costal cartilage, cartilage of an epiphyseal plate, and combinations thereof. In various aspects of the present teachings, the chondrocytes can be extracted from a cadaver at any time following death while the chondrocytes remain viable. In various configurations, chondrocytes can be extracted from a cadaver up to about fourteen days following death. Chondrocytes can be removed from a cadaver from about one hour following death to about fourteen days following death, from greater than 24 hours following death to about thirteen days following death, from about two days following death to about twelve days following death, from about three days following death to about twelve days following death, or from about four days following death to about ten days following death.
- In some embodiments, chondrocytes of the present teachings can be chondrocytes extracted from a cadaver of any chronological age at time of death. In various configurations, chondrocytes can be extracted from a cadaver which is no older than about 40 years of age at time of death, no older than about 30 years of age at time of death, no older than about 20 years of age at time of death, or no older than about 10 years of age at time of death. A donor cadaver need not be a familial member of a recipient, or be otherwise matched immunologically.
- In various embodiments, chondrocytes which are extracted from a cadaver can be grown in vitro prior to their implantation or injection into a recipient patient or purveyance to a treatment provider. Growth of chondrocytes in vitro can be used, for example, to increase the number of chondrocytes available for implantation or injection. In non-limiting example, chondrocyte numbers can be increased about two fold or greater, about ten fold or greater, or about twenty fold or greater. In various configurations, growing chondrocytes in vitro can comprise placing one or more cartilage tissue pieces removed from a cadaver into a tissue culture or cell culture medium which comprises nutrients, buffers, salts, proteins, vitamins and/or growth factors which promote chondrocyte growth, and incubating the chondrocytes. In certain configurations, tissue comprising chondrocytes expressing type II collagen can be dissociated into single cells or small groups of cells prior to, or in conjunction with, their introduction into a culture medium. In addition, in some aspects, in vitro culture of chondrocytes expressing type II collagen can further comprise removing non-chondrocyte cells from a cell- or tissue-culture.
- In various embodiments of the present teachings, chondrocytes expressing type II collagen can be comprised by a composition which can be implanted or injected into an intervertebral disc of a patient in need of treatment. Accordingly, in certain embodiments, the present teachings also include compositions comprising cadaver chondrocytes expressing type II collagen for use in implantation or injection into a degenerative intervertebral disc of a patient in need of treatment. In some configurations of these embodiments, the chondrocytes of these compositions can comprise chondrocytes expressing high molecular weight sulfated proteoglycan. In some configurations, a composition comprising chondrocytes expressing type II collagen can further comprise at least one biocompatible molecule. Non-limiting examples of biocompatible molecules which can be comprised by a composition of the present teachings include fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid (HA), hydrogel, pegylated hydrogel, chitosan, and combinations thereof.
- In various embodiments, the present teachings include methods of forming a composition comprising cadaver chondrocytes. A composition formed by these methods can further comprise one or more biocompatible molecules such as those described supra. Accordingly, methods of these embodiments can comprise contacting cadaver chondrocytes expressing type II collagen with one or more biocompatible molecules, such as, for example, fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid, hydrogel, pegylated hydrogel, chitosan and combinations thereof. The cadaver chondrocytes expressing type II collagen can be, in some configurations, chondrocytes which also express high molecular weight sulfated proteoglycan. In certain aspects, the chondrocytes can be incubated in vitro in a culture medium prior to the contacting with one or more biocompatible molecules.
- In various embodiments, the present teachings include methods of forming a composition comprising cadaver tissue comprising chondrocytes. A composition formed by these methods can further comprise one or more biocompatible molecules such as those described supra. Accordingly, methods of these embodiments can comprise contacting cadaver tissue comprising chondrocytes expressing type II collagen with one or more biocompatible molecules, such as, for example, fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid, hydrogel, pegylated hydrogel, chitosan and combinations thereof. The cadaver chondrocytes expressing type II collagen can be, in some configurations of these embodiments, chondrocytes which also express high molecular weight sulfated proteoglycan. In certain aspects of these embodiments, cadaver tissue comprising chondrocytes expressing type II collagen can be incubated in vitro in a culture medium prior to the contacting with one or more biocompatible molecules.
- In various aspects of the present teachings, a composition comprising both cadaver chondrocytes expressing type II collagen and one or more biocompatible molecules can be implanted or injected into a degenerative intervertebral disc in a patient in need of treatment. In various aspects, implantation or injection of a composition into a disc can comprise implantation or injection of the composition into the annulus of the disc, implantation or injection of the composition into the nucleus pulposus of the disc, implantation or injection of the composition into one or both endplates of the disc, or a combination thereof. In some configurations, an aperture can be formed in an annulus of a degenerative disc, and a composition can be introduced into the disc through the aperture. In some configurations, surgical techniques such as vertebroplasty and kyphoplasty (Garfin, S. R., et al., Spine 26: 1511-1515, 2001) can be adapted or modified for introducing chondrocytes into a degenerative disc of a patient.
- In various embodiments, the present teachings include an apparatus configured for injection of chondrocytes expressing type II collagen to an intervertebral disc of a patient in need of treatment. An apparatus configured for injection of chondrocytes expressing type II collagen into an intervertebral disc can comprise chondrocytes expressing type II collagen. Chondrocytes of these embodiments can comprise chondrocytes expressing high molecular weight sulfated proteoglycan. In various configurations, the apparatus can comprise a composition which comprises the chondrocytes and at least one biocompatible molecule, such as, for example, a biocompatible molecule described supra. In certain embodiments, the chondrocytes expressing type II collagen comprised by the apparatus can be cadaver chondrocytes. The cadaver chondrocytes in these embodiments can be intervertebral disc chondrocytes, or non-intervertebral disc chondrocytes, such as those described supra. In some configurations of these embodiments, the chondrocytes can be comprised by cadaver tissue. An apparatus of the present teachings can further comprise, in some configurations, a syringe, a double syringe, a hollow tube, such as a hollow needle (for example, a Jamshidi needle), a cannula, a catheter, a trocar, a stylet, an obturator, or other instruments, needles or probes for cell or tissue injection, injection, or transfer known to skilled artisans. In certain configurations, the apparatus can be configured for injection of chondrocytes expressing type II collagen into a nucleus pulposus of an intervertebral disc, an annulus of an intervertebral disc, an endplate of an intervertebral disc or a combination thereof.
- In various embodiments of the present teachings, methods are provided for purveying to a treatment provider chondrocytes for repairing a degenerative intervertebral disc in a patient in need thereof. In various aspects, a method of these embodiments can comprise growing cadaver chondrocytes expressing type II collagen in vitro, and delivering the chondrocytes expressing type II collagen to the treatment provider. Chondrocytes expressing type II collagen of these embodiments can be, in some configurations, chondrocytes which also express high molecular weight sulfated proteoglycan. Methods of these embodiments can further comprise obtaining chondrocytes expressing type II collagen from a cadaver. In these embodiments, the cadaver chondrocytes expressing type II collagen can be obtained at various time intervals following death of the donor as described supra. Furthermore, a donor cadaver of chondrocytes expressing type II collagen can be of an age at time of death as described supra. The chondrocytes of these embodiments can be chondrocytes of tissue sources such as those described supra.
- In some configurations of these methods, the chondrocytes expressing type II collagen can be purveyed to a treatment provider along with one or more biocompatible molecules, such as those described supra. In some configurations, a composition comprising the chondrocytes and one or more biocompatible molecules can be purveyed to a treatment provider. In other configurations, the chondrocytes and the one or more biocompatible molecules can be purveyed separately to a treatment provider (either simultaneously or at different times), and the treatment provider can form a composition comprising the chondrocytes and the one or more biocompatible molecules prior to, or in conjunction with, implanting the composition in a patient in need thereof.
- In various embodiments, the teachings of the present application also disclose use of cadaver chondrocytes expressing type II collagen for the production of a composition for repairing a degenerative intervertebral disc in a patient in need thereof. In some configurations of these embodiments, the chondrocytes can also express high molecular weight sulfated proteoglycan. In certain configurations of these embodiments, the chondrocytes can be cadaver chondrocytes which are grown in vitro, as described supra. A composition of these embodiments can comprise a composition comprising cadaver chondrocytes expressing type II collagen and one or more biocompatible molecules such as those described supra. In addition, the time interval following death at which the chondrocytes can be removed from a donor can be a time interval as described supra, and the age of a donor cadaver at time of death can be an age as described supra. In some aspects of these embodiments, the chondrocytes can include chondrocytes removed from an annulus, chondrocytes removed from a nucleus pulposus, chondrocytes removed from an endplate of an intervertebral disc of a donor cadaver, or a combination thereof. In some other aspects of these embodiments, the chondrocytes can be chondrocytes removed from other cartilaginous, non-intervertebral disc tissue of a cadaver, such as, for example, hyaline cartilage from the nose, ears, trachea or larynx, as well as articular cartilage, costal cartilage, cartilage of an epiphyseal plate, or combinations thereof.
- These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, appended claims and accompanying figures where:
-
FIG. 1 illustrates a normal intervertebral disc (left) and a herniated disc (right), -
FIG. 2 illustrates freshly isolated, juvenile cartilage tissue that has been dissected to small cubes and implanted into a damaged nucleus pulposus region of an intervertebral disc in a composition which can also comprise a biocompatible molecule. -
FIG. 3 illustrates isolated juvenile chondrocytes, freshly isolated or harvested from expanded in vitro cultures which can be implanted into the nucleus pulposus region of an intervertebral disc in a composition which can also comprise a biocompatible molecule. -
FIG. 4 illustrates the gross appearance of an intact unoperated disc harvested from the lumbar region of an adult canine. -
FIG. 5 illustrates an intact nucleus pulposus and the cartilaginous endplate of the disc shown inFIG. 4 . -
FIG. 6 illustrates a section of an intervertebral disk that was treated withhuman chondrocytes 12 weeks post-injection. -
FIG. 7 represents the highlighted region ofFIG. 6 , illustrating the newly synthesized matrix that has replaced thenative nucleus 12 weeks after chondrocyte injection. -
FIG. 8 illustrates the gross appearance ofdiscs 12 weeks after chondrocyte injection. - The present teachings describe compositions, methods and devices for repair, replacement and/or supplementation of a degenerative intervertebral disc. These methods can involve implantation or injection of chondrocytes into a degenerative disc. In addition, the present teachings also describe methods for providing chondrocytes to a treatment provider.
- As used herein, the terms “degenerative intervertebral disc” and “degenerative disc” refer to an intervertebral disc exhibiting disease symptoms, abnormalities or malformations, including but not limited to herniations, disruptions, traumatic injuries, and morphological changes associated with or attributed to aging. Indications of a degenerative intervertebral disc can include, but are not limited to, brittleness of an annulus, tearing of an annulus, and shrinking of a nucleus pulposus.
- In various embodiments, the present teaching include methods of repairing a degenerative disc in a human patient in need of treatment. Methods of these embodiments can comprise implanting or injecting into the intervertebral disc a composition comprising cadaver chondrocytes. As used herein, the term “cadaver chondrocytes” refers to viable chondrocytes originally comprised by a human cadaver, as well as clonal descendants of such chondrocytes, such as chondrocytes grown in vitro. Cadaver chondrocytes for use in the various aspects of the present teachings can be obtained from tissues comprising chondrocytes from a cadaver, such as cartilage tissue. Such tissues can be dissected from a cadaver using standard dissection methods well known to skilled artisans. The cartilage tissue utilized in the present teachings can comprise hyaline cartilage, such as cartilage of the nose, ears, trachea and larynx, articular cartilage, costal cartilage, cartilage of an epiphyseal plate, and combinations thereof. In various aspects, the cartilage tissue or chondrocytes can be intervertebral disc cartilage or chondrocytes, or can be cartilage or chondrocytes originating from cartilaginous tissues other than intervertebral disc tissue (herein referred to as “non-intervertebral disc chondrocytes”). Viable chondrocytes can be comprised by cartilaginous tissues in a donor cadaver for up to about two weeks after death of the donor. Accordingly, in some configurations, the time interval from the time of death of a donor (as determined, for example, by a physician or a coroner) to the time of dissection of cartilage tissue from the donor can be any time from about immediately following a pronouncement of death, to about two weeks following death, such as, without limitation, about one hour, greater than 24 hours, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days about ten days, about eleven days, about twelve days, about thirteen days, or about fourteen days after death. In addition, a donor cadaver can be of any chronological age at time of death. For example, a donor cadaver can be, at time of death, ten years old or younger, twenty years old or younger, thirty years old or younger, or forty years old or younger. A donor cadaver need not be a familial member of a recipient, or be otherwise matched immunologically. Without being limited by theory, it is believed that intervertebral cartilage comprises an “immunologically privileged” tissue, so that chondrocytes transplanted to an intervertebral disk are not subject to rejection by the recipient's immune system.
- Cartilage tissue can be removed from a cadaver using any surgical or dissecting techniques and tools known to skilled artisans. Following cartilage removal from a cadaver, the cartilage tissue can be minced, dissociated into single cells or small groups of cells, and/or placed into tissue or cell culture using standard techniques and apparatuses well known to skilled artisans, such as techniques and apparatuses described in the these references. Non-limiting descriptions of methods of cartilage and chondrocyte removal and culture can be found in references such as, for example, Feder, J. et al. in: Tissue Engineering in Musculoskeletal Clinical Practice. American Academy of Orthopaedic Surgeons, 2004; Adkisson, H. D. et al., Clin. Orthop. 391S:S280-S294, 2001; and U.S. Pat. Nos. 6,235,316 and 6,645,316 to Adkisson.
- Cadaver chondrocytes used in the various embodiments of the present teachings are all cadaver chondrocytes which express type II collagen. In addition, in some aspects, cadaver chondrocytes can comprise chondrocytes expressing other molecular markers such as a high molecular weight sulfated proteoglycan, such as, for example, chondroitin sulfate (Kato, Y., and Gospodarowicz, D., J. Cell Biol. 100: 477-485. 1985). Presence of such markers can be determined using materials and methods well known to skilled artisans, such as, for example, antibody detection and histological staining.
- In some configurations, cadaver chondrocytes or cartilage, including cartilage tissue as well as cells, either directly extracted from a cadaver grown in vitro, can be harvested prior to implantation or injection into a patient using cell culture techniques and apparatuses well known to skilled artisans, such as culture methods for neocartilage described in U.S. Pat. Nos. 6,235,316 and 6,645,316 to Adkisson, and other general laboratory manuals on cell culture such as Sambrook, J. et al., Molecular Cloning: a Laboratory Manual (Third Edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; and Spector, D. L., et al., Culture and Biochemical Analysis of Cells, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 1998. In vitro culture of cadaver chondrocytes can be used to increase numbers of chondrocytes which can be implanted into a patient. In addition, routine laboratory measures known to skilled artisans can be used to detect and remove non-chondrocyte cells from a cell culture, or to test a culture for the presence of biological contaminants such as microorganisms and viruses. Primary cultures established starting from cadaver chondrocytes can be grown as long as the chondrocytes remain viable and maintain their normal in vitro histological properties.
- Various configurations of the present teachings include compositions comprising chondrocytes and one or more biocompatible molecules. These biocompatible molecules can include molecules that enhance survival an/or integration of implanted chondrocytes or cartilaginous tissues into an intervertebral disc. Examples of such molecules include, without limitation, fibrinogen, fibrin, thrombin, type I collagen, type II collagen, type III collagen, fibronectin, laminin, hyaluronic acid, hydrogel, pegylated hydrogel, chitosan, and combinations thereof. Various commercial formulations comprising such molecules, such as, for example, Tisseel® fibrin glue (Baxter Healthcare Corporation, Westlake Village, Calif.) can comprise a composition of the present teachings. Accordingly, a composition of the present teachings can comprise, in non-limiting example, chondrocytes grown in culture and Tisseel® fibrin glue.
- In various methods of the present teachings, cadaver chondrocytes, including but not limited to cadaver chondrocytes grown in vitro and cartilage tissue maintained in tissue culture in vitro, can be implanted or injected into an intervertebral disc of a recipient patient using surgical methods and apparatuses known to skilled artisans but adapted for such use. In various configurations, chondrocytes or cartilage of the present teachings can be implanted or injected into an annulus of a degenerative intervertebral disc, a nucleus pulposus of an intervertebral disc, one or both endplates of a degenerative intervertebral disc, or a combination thereof. In certain aspects, an aperture can be introduced into the annulus of an intervertebral disc. The aperture can provide a path for introducing chondrocytes or cartilage tissue into a disc.
- In various configurations, cells or tissue can be placed into an apparatus or device configured for transfer of chondrocytes to or from an intervertebral disc patient, such as, in non-limiting example a biopsy instrument or transplantation instrument comprising a hollow tube or needle, a syringe, a double syringe, a hollow tube, a hollow needle such as a Jamshidi needle, a Cook needle (Cook incorporated, Bloomington, Ind. USA), a cannula, a catheter, a trocar, a stylet, an obturator, or other instruments, needles or probes for cell or tissue injection, injection, or transfer known to skilled artisans. Accordingly, an apparatus of the present teachings can comprise cadaver chondrocytes as described above, as well as at least one hollow needle or tube through which the chondrocytes can be introduced into an intervertebral disc of a patient. In some configurations, the apparatus comprises a composition comprising the chondrocytes as well as at least one biocompatible molecule as described supra. These apparatuses can be configured for implanting or injecting chondrocytes into an annulus, a nucleus pulposus, and/or an endplate of a degenerative disc. Furthermore, surgical techniques such as vertebroplasty and kyphoplasty (Garfin, S. R., et al., Spine 26: 1511-1515, 2001) can be adapted for introduction of chondrocytes into a degenerative disc of a patient. In non-limiting example, an instrument for such as a bone tamp/balloon can be inserted into a degenerative intervertebral disc, and used to create or expand a space or cavity within a degenerative disc, for example in the nucleus pulposus of the disc. The balloon can be removed, and chondrocytes expressing type II collagen can then be injected into the expanded space, for example through a catheter.
- In any embodiment the one or more biocompatible molecules may form a chondro-conductive/inductive matrix, carrier, or milieu that comprises, for example, fibrinogen. The fibrinogen may be from any suitable source. For example, one skilled in the art will recognize that fibrinogen may be derived from blood bank products—either heterologous (pooled or single-donor) or autologous cryoprecipitate or fresh frozen plasma. Fibrinogen can also be derived from autologous fresh or platelet-rich plasma, obtained using cell-saver or other techniques. U.S. Pat. No. 5,834,420 discloses a method for obtaining fibrinogen.
- In any embodiment the one or more biocompatible molecules may comprise thrombin. The thrombin may be from any suitable source. One skilled in the art will recognize that thrombin can be isolated by well known means or purchased commercially. See U.S. Pat. No. 4,965,203 and Berliner, J L (Ed), THROMBIN: STRUCTURE AND FUNCTION, Plenum Pub Corp. (1992) for exemplary methods of isolation and/or purification.
- In any embodiment the one or more biocompatible molecules may comprise collagen, hyaluronic acid, fibrinogen, thrombin or any combination thereof. The biocompatible molecules in combination may contain equal proportions of each constituent molecule or more of any one or group of the constituents than other(s). When used in combination the collagen, hyaluronic acid, fibrinogen and thrombin may be in any proportion, ranging from one part of one, or one part of a combination of two or more of them compared to the amount of the other(s), up to equal proportions of each constituent.
- When practicing any embodiment of the invention that comprises collagen, hyaluronic acid, fibrinogen, thrombin or any combination thereof, the fibrinogen and thrombin components should be kept separate prior to the time of use. A common type of applicator that may be used for this purpose consists of a double syringe, joined by a Y-connector where the components mix as they emerge. This type of applicator, used with a blunt cannula, is useful for combining of the collagen, hyaluronic acid, thrombin and the fibrinogen and also useful in the methods of the invention for disposing or transplanting the inventive compositions to a site wherein repair, replacement or supplementation of an intervertebral disc is desired.
- In various embodiments the one or more biocompatible molecules may comprise one or more of collagen, hyaluronic acid, fibrinogen, thrombin, fibrinogen/thrombin (Tisseel), Albumin, in-situ forming PEG hydrogel, fibrin, hyaluronate, fibrin/hyaluronate, collagen/hyaluronate, fibrin/collagen/hyaluronate, PEG/hyaluronate, PEG/collagen, PEG base sealants (CoSeal) or other plasma and protein-based adhesives and/or sealants other natural adhesives and/or sealants and combinations thereof that are biocompatible with regard to the intervertebral nucleus pulposus repair, replacement or supplementation.
- In use in the method embodiments of the invention, the composition may be disposed in an intervertebral disc in need of repair, replacement or supplementation by being injected through the disc annulus into the center of the damaged disc nucleus. As the delivery needle, trochanter or portal is withdrawn, additional material may usefully be injected into the track created in the annulus. In all cases it is expected that the hyaline cartilage completely fills the nucleus space and fully integrates with the annulus. It is further presumed that the hyaline cartilage comprises of neocartilage or juvenile cartilage and/or cells will also be useful in repairing damaged annulus.
- In various embodiments and configurations, the present teachings also disclose methods of purveying to a treatment provider chondrocytes for repairing a degenerative intervertebral disc in a patient in need thereof. These methods can comprise obtaining chondrocytes from a cadaver, growing the chondrocytes in vitro, then delivering the chondrocytes to the treatment provider. The chondrocytes can be obtained from a cadaver using methods described supra, and can be chondrocytes which are adapted for injection into a degenerative intervertebral disc in a patient. The adaptation can comprise, in various configurations, expanding the numbers of chondrocytes through growth in vitro. Chondrocytes adapted for injection can also comprise, in certain aspects, chondrocytes which can be loosely connected or unattached to each other, and can be chondrocytes not comprised by cartilage tissue. The cadaver chondrocytes of these embodiments can be chondrocytes expressing type II collagen, as described supra, and can also be chondrocytes expressing high molecular weight sulfated proteoglycan, also as described supra. The chondrocytes can be delivered to a treatment provider, as either a chondrocytes grown in vitro and/or as cartilage tissue pieces as described supra. The treatment provider can be, in non-limiting example, a physician such as an orthopedic surgeon, or an agent or employee of the physician or a health care institution such as a hospital or outpatient clinic. Accordingly, in non-limiting example, cadaver chondrocytes can be grown in vitro, and delivered to the treatment provider via a delivery service such as, for example, a courier or an overnight shipper. Cadaver chondrocytes and/or cartilage tissue can be prepared for delivering by methods well known to skilled artisans. In some configurations, cadaver chondrocytes and/or cartilage tissue can be provided in a composition further comprising at least one biocompatible molecule as described supra. In alternative configurations, the chondrocytes and/or cartilage tissue can be packaged and sent separately from any biomolecule(s). The treatment provider can then form the composition by mixing the cells with the one or more biomolecules. In some aspects, the mixing can be done immediately prior to implanting the cells into a recipient patient.
- The following example illustrates transplantation and survival of human chondrocytes transplanted into canine intervertebral disc tissue. In this example, a pilot animal study was conducted to determine whether human articular chondrocytes survive injection to produce cartilaginous matrices in experimental defects created in the intervertebral disk of adult canines. Gross morphologic and histological results obtained from this short-term pilot study (12 weeks) demonstrate that implanted chondrocytes can survive to produce cartilaginous matrices which integrate with surrounding host tissues.
- Surgical Procedure: Prior to induction of anesthesia, six adult female dogs were sedated by the attending veterinarian or the veterinary technician/anesthetist using one of the following combinations: Atropine 0.05 mg/kg IM with or without Acepromizine 0.05-0.2 mg/kg IM. An 18 or 20 gauge 1¼ to 2 inch angio-catheter was placed in the cephalic saphenous or auricular vein for venous access. General anesthesia was induced with Pentothal (10-20 mg/kg IV to effect). Animals were intubated with a 7.0 mm-9.0 mm hi-low pressure cuff endotracheal tube. Anesthesia was maintained with isoflurane 2.5-4% in an air-oxygen mixture of 40-60%. The tube was connected to low-pressure continuous suction, and mechanical ventilation was initiated and maintained at 10 ml/kg tidal volume and at a rate of 8-10/minute. Crystalloids were provided at a rate of 7-10 mg/kg/hr.
- Surgical exposure consisted of a 10 cm incision along the abdominal midline, followed by soft tissue dissection to permit transperitoneal exposure of the anterior lumbar spine.
- Blunt dissection using a Cobb elevator and electrocautery was performed as needed to expose the anterior aspects of the L3-L4, L5-L6, and L7-S1 intervertebral disc space. Surgical defects (1×3 mm) were created through the annulus into the disc nucleus using a 16 gauge biopsy needle (Jamshidi needle) and aspiration. A significant volume of the nucleus was removed in concert with the annulus.
- Human Neocartilage produced at ISTO Technologies according to U.S. Pat. Nos. 6,235,316 and 6,645,764 were enzymatically dissociated in HL-1 Serum-free Medium (Cambrex Bio Science, Walkersville, Md.) containing 60 units/ml CLS4 collagenase (Worthington, Lakewood, N.J.) and 50 units/mL hyaluronidase (Sigma, St. Louis, Mo.). The dissociated chondrocytes (derived from the articular cartilage of a six year old individual) were washed in fresh HL-1 medium and briefly exposed to 0.25% EDTA before pelleting at 500×g for 7 minutes. The cells were counted and stored in sterile cryovials until use. Chondrocyte viability was estimated to be greater than 90% by trypan blue exclusion. Six tubes were prepared each containing 2 million chondrocytes. The cells were then pelleted and the supernate removed. These samples were hand carried to the operating room on wet ice. Once defects were created, a chondrocyte suspension was prepared using 100 microliters of thrombin solution (Tisseel®, Baxter Healthcare Corporation, Westlake Village, Calif.). This step was completed immediately before mixing with an equivalent volume of the fibrin component (Tisseel®) using the Tisseel® injection device. 150-200 microliters of the cell suspension was injected into the intervertebral disk closest to the dog's tail (L7-S1 and L5-L6), whereas the highest vertebral level to be treated (L3-L4 or L4-L5) was filled with 100-150 microliters of cells or cell carrier. The cell suspension was injected at the base of the defect through a needle and withdrawn during expulsion until it began to spill out of the injection site, forming a solid gel. Two thirds of the control defects were left untreated (33%) or received fibrin carrier alone (33%). The final one-third of operated defects was treated with cells suspended in fibrin carrier as described above. Treatment at each of the levels was randomized to control for variability in disc size and location.
- Following the surgical procedure, the fascia and underlying muscles were closed in an interrupted fashion using -0- Prolene and the skin approximated using Vicryl® (Ethicon, Inc. Somerville, N.J. USA) and Vetbond™ tissue adhesive (3M, St. Paul, Minn. USA). Blood loss, operative times and both intra- and peri-operative complications were recorded. Observations of ambulatory activities and wound healing were monitored daily, and all animals received analgesics after surgery.
- Post-operative Care: After recovery from anesthesia, each dog was returned to its cage and housed singly for observation (daily) by veterinary technicians for any sign of adverse events related to surgery. Buprinorphine (0.01-0.02 mg/k IM or SC) was administered for relief of pain every 12 hours for the first 24 hours and prn thereafter. In general, the animals were pain free after 24 hrs.
- Animal Harvest and Sample Collection: Dogs were sacrificed 12 weeks after surgery by overdose with euthanasia solution. Spines were removed, keeping the upper lumbar and sacral region intact. Musculoskeletal tissue was removed by dissection to expose the vertebral bodies for further sectioning using a band saw. Gross observation of the defects was performed using digital photography and the samples were immediately fixed in 10% neutral buffered formalin (Fisher Scientific, Fairlawn, N.J.) for 48 hrs. Samples were subsequently decalcified in 10% disodium EDTA (Sigma-Aldrich Co., St. Louis, Mo.) after four washes in PBS to remove formalin. Samples were then dehydrated in a graded alcohol series and processed using standard paraffin embedding.
- Five micron sections were cut and stained with hematoxylin and eosin as well as safraninO for microscopic evaluation of the cartilaginous tissue present in control and operated intervertebral disks. Discs that were not exposed to the surgical procedures were used to establish normal histological features of the canine intervertebral disk.
- Results: In general, the dogs handled the surgical procedure well, and all of the abdominal wounds healed rapidly without infection. There appeared to be no detrimental effect of multiple surgical procedures (operation at three vertebral levels in each animal) on the activity level of all dogs.
- Gross macroscopic observation of the dissected vertebrae revealed normal disc structure in those discs that were not subjected to surgical intervention (
FIG. 4 ). A glistening gelatinous center, corresponding to the nucleus pulposus, was identifiable in every case. Histological analysis revealed normal disc morphology in which the concentric rings of the annulus were observed to contain lower sulfated glycosaminoglycan content (fibrocartilaginous tissue) than the nucleus pulposus (NP) and the cartilage end plates (hyaline tissue), suggesting that surgical intervention at an adjacent level did not alter the morphological features of a disc that was not part of the procedure (FIG. 5 ). - Those discs receiving neocartilage chondrocytes in fibrin glue were observed to contain viable chondrocytes in the disc space, and the injected chondrocytes had synthesized a hyaline matrix enriched in sulfated proteoglycan (
FIGS. 6 and 7 ). Gross macroscopic observation of treated discs show viable cartilaginous tissue occupying the disc space (FIGS. 8A and B). - These results indicate that fibrin delivery to the disc space of chondrocytes derived from juvenile articular was successful and that the nature of newly synthesized tissue produced by the implanted chondrocytes appeared to be cartilaginous as determined by SafraninO staining. Most importantly, there was no histological evidence of lymphocytic infiltration into the
operative site 12 weeks post-injection, suggesting that there was no immunologic rejection. -
FIG. 4 illustrates the gross appearance of an intact unoperated disc harvested from the lumbar region of an adult canine. The disc is split in half to show the morphology of a normal intervertebral disk. The annulus fibrosus is the outer fibrocartilaginous structure surrounding the inner jelly-like structure or nucleus pulposus (NP). The cartilage endplate covers the surface of the upper and lower vertebral body. -
FIG. 5 illustrates an intact nucleus pulposus and the cartilaginous endplate of the disc shown inFIG. 4 . The section was stained with Safranin O to identify sulfated glycosaminoglycans in the NP and in the cartilage end plate. Notice that the NP chondrocytes are significantly larger than chondrocytes of the cartilage endplate and that the endplate contains greater levels of sulfated proteoglycan. Original magnification 100× -
FIG. 6 illustrates a Safranin O-stained section of an intervertebral disk that was treated withhuman chondrocytes 12 weeks post-injection. The chondrocytes are viable and have synthesized a cartilaginous matrix that is highly enriched in sulfated glycosaminoglycans. The injected chondrocytes are much smaller than native NP chondrocytes identified inFIG. 5 . The white square identifies the region shown inFIG. 7 . Original magnification 40×. -
FIG. 7 represents the highlighted region ofFIG. 6 , illustrating the newly synthesized matrix that has replaced thenative nucleus 12 weeks after chondrocyte injection. The new matrix appears to be integrated well with the surrounding native tissues. Chondrocytes in this newly synthesized matrix (identified with white dotted circles) appear to be randomly distributed and of similar size to chondrocytes of the cartilaginous endplate. Original magnification 100× -
FIG. 8 is in two parts. Panel A illustrates the gross appearance of adisc 12 weeks after chondrocyte injection. The native nucleus is no longer present and is replaced by newly synthesized cartilaginous tissue. Panel B illustrates the gross appearance of another disc treated in the same manner. The histological features of this disc are shown inFIGS. 6 and 7 . The newly synthesized cartilaginous material produced after chondrocyte injection is expected to remodel and take on morphological features that are more characteristic of the native annulus and nucleus within 1 year after treatment. - It is to be understood that the present invention has been described in detail by way of illustration and example in order to acquaint others skilled in the art with the invention, its principles, and its practical application. Particular formulations and processes of the present invention are not limited to the descriptions of the specific embodiments presented, but rather the descriptions and examples should be viewed in terms of the claims that follow and their equivalents. While some of the examples and descriptions above include some conclusions about the way the invention may function, the inventors do not intend to be bound by those conclusions and functions, but put them forth only as possible explanations.
- It is to be further understood that the specific embodiments of the present invention as set forth are not intended as being exhaustive or limiting of the invention, and that many alternatives, modifications, and variations will be apparent to those of ordinary skill in the art in light of the foregoing examples and detailed description. Accordingly, this invention is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and scope of the following claims.
- All publications, patents, patent applications and other references cited in this application are herein incorporated by reference in their entirety as if each individual publication, patent, patent application or other reference were specifically and individually indicated to be incorporated by reference.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/058,193 US20080299214A1 (en) | 2004-02-20 | 2008-03-28 | Intervertebral Disc Repair, Methods and Devices Therefor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54661904P | 2004-02-20 | 2004-02-20 | |
US11/063,183 US7879604B2 (en) | 2004-02-20 | 2005-02-22 | Intervertebral disk repair, methods and devices therefor |
US12/058,193 US20080299214A1 (en) | 2004-02-20 | 2008-03-28 | Intervertebral Disc Repair, Methods and Devices Therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/063,183 Continuation US7879604B2 (en) | 2004-02-20 | 2005-02-22 | Intervertebral disk repair, methods and devices therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080299214A1 true US20080299214A1 (en) | 2008-12-04 |
Family
ID=34910797
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/063,183 Active 2025-07-06 US7879604B2 (en) | 2004-02-20 | 2005-02-22 | Intervertebral disk repair, methods and devices therefor |
US12/058,193 Abandoned US20080299214A1 (en) | 2004-02-20 | 2008-03-28 | Intervertebral Disc Repair, Methods and Devices Therefor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/063,183 Active 2025-07-06 US7879604B2 (en) | 2004-02-20 | 2005-02-22 | Intervertebral disk repair, methods and devices therefor |
Country Status (4)
Country | Link |
---|---|
US (2) | US7879604B2 (en) |
EP (1) | EP1753860B1 (en) |
AT (1) | ATE553186T1 (en) |
WO (1) | WO2005081870A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080269895A1 (en) * | 2005-09-20 | 2008-10-30 | Steinwachs Matthias R | Implant for the Repair of a Cartilage Defect and Method for Manufacturing the Implant |
US8480757B2 (en) | 2005-08-26 | 2013-07-09 | Zimmer, Inc. | Implants and methods for repair, replacement and treatment of disease |
US8497121B2 (en) | 2006-12-20 | 2013-07-30 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US8518433B2 (en) | 2003-12-11 | 2013-08-27 | Zimmer, Inc. | Method of treating an osteochondral defect |
US9133438B2 (en) | 2011-06-29 | 2015-09-15 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
US10167449B2 (en) | 2013-04-19 | 2019-01-01 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
US20040054414A1 (en) | 2002-09-18 | 2004-03-18 | Trieu Hai H. | Collagen-based materials and methods for augmenting intervertebral discs |
CN100394989C (en) | 2002-11-15 | 2008-06-18 | 华沙整形外科股份有限公司 | Collagen-based materials and methods for augmenting intervertebral discs |
US8163018B2 (en) | 2006-02-14 | 2012-04-24 | Warsaw Orthopedic, Inc. | Treatment of the vertebral column |
US8016859B2 (en) | 2006-02-17 | 2011-09-13 | Medtronic, Inc. | Dynamic treatment system and method of use |
US8399619B2 (en) | 2006-06-30 | 2013-03-19 | Warsaw Orthopedic, Inc. | Injectable collagen material |
US8118779B2 (en) | 2006-06-30 | 2012-02-21 | Warsaw Orthopedic, Inc. | Collagen delivery device |
DE602007011574D1 (en) * | 2007-05-02 | 2011-02-10 | Klinikum Mannheim Gmbh | Implantable system for an intervertebral disc and an intervertebral disc implant |
KR20170073614A (en) * | 2008-03-21 | 2017-06-28 | 티슈진, 인코포레이티드 | Composition for treatment of intervertebral disc degeneration |
US8529933B2 (en) | 2009-07-27 | 2013-09-10 | Warsaw Orthopedic, Inc. | Biphasic calcium phosphate cement for drug delivery |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4359049A (en) * | 1980-04-02 | 1982-11-16 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Apparatus for applying a tissue adhesive on the basis of human or animal proteins |
US4536392A (en) * | 1983-06-27 | 1985-08-20 | Queen's University At Kingston | Method for controlling hemophilia in mammals |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
US5516532A (en) * | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6074663A (en) * | 1995-01-16 | 2000-06-13 | Baxter International Inc. | Method of using cross-linked fibrin material |
US6132463A (en) * | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
US6235316B1 (en) * | 1997-04-04 | 2001-05-22 | Barnes-Jewish Hospital | Neocartilage and methods of use |
US20010014475A1 (en) * | 1998-04-08 | 2001-08-16 | Frondoza Carmelita G. | Method for fabricating cell-containing implants |
US20010051834A1 (en) * | 1999-03-24 | 2001-12-13 | Chondros, Inc. | Method for composite cell-based implants |
US6340369B1 (en) * | 1999-08-13 | 2002-01-22 | Bret A. Ferree | Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix |
US6352557B1 (en) * | 1999-08-13 | 2002-03-05 | Bret A. Ferree | Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells |
US20020082623A1 (en) * | 1999-07-28 | 2002-06-27 | Kurt Osther | Vitro repair of bone and/or cartilage defects |
US20020103542A1 (en) * | 2000-09-18 | 2002-08-01 | Bilbo Patrick R. | Methods for treating a patient using a bioengineered flat sheet graft prostheses |
US6428576B1 (en) * | 1999-04-16 | 2002-08-06 | Endospine, Ltd. | System for repairing inter-vertebral discs |
US6703038B1 (en) * | 1999-11-24 | 2004-03-09 | Universitaetsklinikum Freiburg | Injectable bone substitute material containing non-ceramic hydroxyapatite cement |
US20040219182A1 (en) * | 2003-04-29 | 2004-11-04 | Gomes Katherine A. | Novel glue for cartilage repair |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE35694E (en) * | 1984-07-16 | 1997-12-16 | Celtrix Pharmaceuticals, Inc. | Polypeptide cartilage-inducing factors found in bone |
US4965203A (en) * | 1987-01-28 | 1990-10-23 | Warner-Lambert Company | Purified thrombin preparations |
US5047055A (en) * | 1990-12-21 | 1991-09-10 | Pfizer Hospital Products Group, Inc. | Hydrogel intervertebral disc nucleus |
US5192326A (en) * | 1990-12-21 | 1993-03-09 | Pfizer Hospital Products Group, Inc. | Hydrogel bead intervertebral disc nucleus |
US5326357A (en) * | 1992-03-18 | 1994-07-05 | Mount Sinai Hospital Corporation | Reconstituted cartridge tissue |
US5879359A (en) * | 1992-08-03 | 1999-03-09 | Fidia S.P.A. | Biodegradable guide channels comprised of esters of hyaluronic acid for use in tissue repair as surgical aids |
US5834420A (en) * | 1994-07-14 | 1998-11-10 | Croix-Rouge De Belgique | Fibrinogen concentrate obtained from blood plasma, process and plant for its preparation |
DE69532856T2 (en) * | 1994-10-17 | 2005-04-21 | Raymedica Inc | Spinal disc-GRAFT |
US5824093A (en) * | 1994-10-17 | 1998-10-20 | Raymedica, Inc. | Prosthetic spinal disc nucleus |
CA2252860C (en) * | 1996-05-28 | 2011-03-22 | 1218122 Ontario Inc. | Resorbable implant biomaterial made of condensed calcium phosphate particles |
GB9704749D0 (en) * | 1997-03-07 | 1997-04-23 | Univ London | Tissue Implant |
US6022376A (en) * | 1997-06-06 | 2000-02-08 | Raymedica, Inc. | Percutaneous prosthetic spinal disc nucleus and method of manufacture |
WO1999004720A1 (en) | 1997-07-11 | 1999-02-04 | Reprogenesis Inc. | Repair of intervertebral disks |
US6027744A (en) * | 1998-04-24 | 2000-02-22 | University Of Massachusetts Medical Center | Guided development and support of hydrogel-cell compositions |
US6224630B1 (en) * | 1998-05-29 | 2001-05-01 | Advanced Bio Surfaces, Inc. | Implantable tissue repair device |
US6132465A (en) * | 1998-06-04 | 2000-10-17 | Raymedica, Inc. | Tapered prosthetic spinal disc nucleus |
US6206921B1 (en) * | 1999-02-22 | 2001-03-27 | Peter A. Guagliano | Method of replacing nucleus pulposus and repairing the intervertebral disk |
US6110210A (en) * | 1999-04-08 | 2000-08-29 | Raymedica, Inc. | Prosthetic spinal disc nucleus having selectively coupled bodies |
US6645316B1 (en) * | 1999-05-28 | 2003-11-11 | Henkel Kommanditgesellschaft Auf Aktien | Post-passivation of a phosphatized metal surface |
US6371990B1 (en) * | 1999-10-08 | 2002-04-16 | Bret A. Ferree | Annulus fibrosis augmentation methods and apparatus |
US6454804B1 (en) * | 1999-10-08 | 2002-09-24 | Bret A. Ferree | Engineered tissue annulus fibrosis augmentation methods and apparatus |
US6793677B2 (en) * | 1999-08-13 | 2004-09-21 | Bret A. Ferree | Method of providing cells and other biologic materials for transplantation |
US6685695B2 (en) * | 1999-08-13 | 2004-02-03 | Bret A. Ferree | Method and apparatus for providing nutrition to intervertebral disc tissue |
US6648920B2 (en) * | 1999-10-08 | 2003-11-18 | Bret A. Ferree | Natural and synthetic supplements to engineered annulus and disc tissues |
US6723335B1 (en) * | 2000-04-07 | 2004-04-20 | Jeffrey William Moehlenbruck | Methods and compositions for treating intervertebral disc degeneration |
US6921532B1 (en) * | 2000-06-22 | 2005-07-26 | Spinal Restoration, Inc. | Biological Bioadhesive composition and methods of preparation and use |
AU2002221370A1 (en) * | 2000-11-15 | 2002-05-27 | Bio Syntech Canada Inc | Method for restoring a damaged or degenerated intervertebral disc |
US6645761B1 (en) * | 2000-12-22 | 2003-11-11 | Stratagene | Humanized polynucleotide sequence encoding Renilla mulleri green fluorescent protein |
-
2005
- 2005-02-22 AT AT05723321T patent/ATE553186T1/en active
- 2005-02-22 US US11/063,183 patent/US7879604B2/en active Active
- 2005-02-22 WO PCT/US2005/005282 patent/WO2005081870A2/en not_active Application Discontinuation
- 2005-02-22 EP EP05723321A patent/EP1753860B1/en active Active
-
2008
- 2008-03-28 US US12/058,193 patent/US20080299214A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4359049A (en) * | 1980-04-02 | 1982-11-16 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Apparatus for applying a tissue adhesive on the basis of human or animal proteins |
US4536392A (en) * | 1983-06-27 | 1985-08-20 | Queen's University At Kingston | Method for controlling hemophilia in mammals |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
US5516532A (en) * | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
US6074663A (en) * | 1995-01-16 | 2000-06-13 | Baxter International Inc. | Method of using cross-linked fibrin material |
US6132463A (en) * | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6235316B1 (en) * | 1997-04-04 | 2001-05-22 | Barnes-Jewish Hospital | Neocartilage and methods of use |
US20010014475A1 (en) * | 1998-04-08 | 2001-08-16 | Frondoza Carmelita G. | Method for fabricating cell-containing implants |
US20010051834A1 (en) * | 1999-03-24 | 2001-12-13 | Chondros, Inc. | Method for composite cell-based implants |
US6428576B1 (en) * | 1999-04-16 | 2002-08-06 | Endospine, Ltd. | System for repairing inter-vertebral discs |
US20020082623A1 (en) * | 1999-07-28 | 2002-06-27 | Kurt Osther | Vitro repair of bone and/or cartilage defects |
US6340369B1 (en) * | 1999-08-13 | 2002-01-22 | Bret A. Ferree | Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix |
US6352557B1 (en) * | 1999-08-13 | 2002-03-05 | Bret A. Ferree | Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells |
US6703038B1 (en) * | 1999-11-24 | 2004-03-09 | Universitaetsklinikum Freiburg | Injectable bone substitute material containing non-ceramic hydroxyapatite cement |
US20020103542A1 (en) * | 2000-09-18 | 2002-08-01 | Bilbo Patrick R. | Methods for treating a patient using a bioengineered flat sheet graft prostheses |
US20040219182A1 (en) * | 2003-04-29 | 2004-11-04 | Gomes Katherine A. | Novel glue for cartilage repair |
Non-Patent Citations (3)
Title |
---|
Chang J et al. 2007. Injectable tissue-engineered cartilage using a fibrin sealant. Arch Facial Plast Surg 9: 161-166. * |
Passaretti D et al. 2001. Cultured chondrocytes produce injectable tissue-engineered cartilage in hydrogel polymer. Tissue Eng 7: 805-815. * |
Silverman RP et al. 1999. Injectable tissue-engineered cartilage using a fibrin glue polymer. Plast Reconstr Surg 103: 1809-1818. * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8834914B2 (en) | 2003-12-11 | 2014-09-16 | Zimmer, Inc. | Treatment methods using a particulate cadaveric allogenic juvenile cartilage particles |
US8518433B2 (en) | 2003-12-11 | 2013-08-27 | Zimmer, Inc. | Method of treating an osteochondral defect |
US8524268B2 (en) | 2003-12-11 | 2013-09-03 | Zimmer, Inc. | Cadaveric allogenic human juvenile cartilage implant |
US8652507B2 (en) | 2003-12-11 | 2014-02-18 | Zimmer, Inc. | Juvenile cartilage composition |
US8765165B2 (en) | 2003-12-11 | 2014-07-01 | Zimmer, Inc. | Particulate cartilage system |
US8784863B2 (en) | 2003-12-11 | 2014-07-22 | Zimmer, Inc. | Particulate cadaveric allogenic cartilage system |
US8480757B2 (en) | 2005-08-26 | 2013-07-09 | Zimmer, Inc. | Implants and methods for repair, replacement and treatment of disease |
US8945535B2 (en) | 2005-09-20 | 2015-02-03 | Zimmer Orthobiologics, Inc. | Implant for the repair of a cartilage defect and method for manufacturing the implant |
US20080269895A1 (en) * | 2005-09-20 | 2008-10-30 | Steinwachs Matthias R | Implant for the Repair of a Cartilage Defect and Method for Manufacturing the Implant |
US8497121B2 (en) | 2006-12-20 | 2013-07-30 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
US11851682B2 (en) | 2011-06-29 | 2023-12-26 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US10597638B2 (en) | 2011-06-29 | 2020-03-24 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US11066646B2 (en) | 2011-06-29 | 2021-07-20 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US9133438B2 (en) | 2011-06-29 | 2015-09-15 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
US10167449B2 (en) | 2013-04-19 | 2019-01-01 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
US10941383B2 (en) | 2013-04-19 | 2021-03-09 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
US11667892B2 (en) | 2013-04-19 | 2023-06-06 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
Also Published As
Publication number | Publication date |
---|---|
US7879604B2 (en) | 2011-02-01 |
WO2005081870A3 (en) | 2006-12-14 |
ATE553186T1 (en) | 2012-04-15 |
EP1753860A2 (en) | 2007-02-21 |
US20050196387A1 (en) | 2005-09-08 |
EP1753860A4 (en) | 2008-05-21 |
WO2005081870A2 (en) | 2005-09-09 |
EP1753860B1 (en) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7879604B2 (en) | Intervertebral disk repair, methods and devices therefor | |
US20160235890A1 (en) | Intervertebral disc repair, methods and devices therefor | |
US6365405B1 (en) | Compositions of chondrocytes, preparation and utilization | |
US6454804B1 (en) | Engineered tissue annulus fibrosis augmentation methods and apparatus | |
O'DRISCOLL | Current concepts review-the healing and regeneration of articular cartilage | |
US6340369B1 (en) | Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix | |
JP6980004B2 (en) | Cartilage regeneration composition and its manufacturing method | |
US20080014179A1 (en) | Tissue transplantation compositions and methods | |
US20010006634A1 (en) | Bonding of cartilaginous matrices using isolated chondrocytes | |
KR20150048115A (en) | Disrupted cartilage products | |
Kazemi et al. | Effect of autologous platelet rich fibrin on the healing of experimental articular cartilage defects of the knee in an animal model | |
US6755863B2 (en) | Rotator cuff repair using engineered tissues | |
US20030026788A1 (en) | Use of extracellular matrix tissue to preserve cultured cell phenotype | |
Paddle-Ledinek et al. | Skin replacement by cultured keratinocyte grafts: an Australian experience | |
JP2010537968A (en) | Compositions suitable for the treatment of spinal cord diseases, disorders or symptoms | |
JP2004524839A (en) | In vitro improved method of culturing mammalian cells for autologous cell implantation / transplantation method | |
CN108014339A (en) | For treating the fibroblast of degenerative disc disease | |
AU2004230980B2 (en) | Process for producing cartilage cells for transplantation | |
WO1996003160A1 (en) | Fibrin-cell suspension for construction of new tissue | |
Bruns et al. | The rib perichondrium: an anatomical study in sheep of a tissue used as transplant in the treatment of hyaline-cartilage defects | |
Szeparowicz et al. | Is the repair of articular cartilage lesion by costal chondrocyte transplantation donor age-dependent? An experimental study in rabbits. | |
JP5373427B2 (en) | Use of synovial cells and minced cartilage fragments in cartilage repair | |
Roseti et al. | Development of Human Chondrocyte–Based Medicinal Products for Autologous Cell Therapy | |
Fornasari | Livia Roseti1, Alessandra Bassi1, Brunella Grigolo2 and | |
Chanlalit et al. | Autologous Chondrocyte Implantation (ACI) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VELOCITY FINANCIAL GROUP INC., ITS SUCCESSORS AND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ISTO TECHNOLOGIES, INC., A DELAWARE CORP.;REEL/FRAME:021805/0354 Effective date: 20080930 |
|
AS | Assignment |
Owner name: ISTO TECHNOLOGIES, INC.,MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:VELOCITY VENTURE FUNDING, L.L.C.;REEL/FRAME:024563/0606 Effective date: 20100621 Owner name: ISTO TECHNOLOGIES, INC., MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:VELOCITY VENTURE FUNDING, L.L.C.;REEL/FRAME:024563/0606 Effective date: 20100621 |
|
AS | Assignment |
Owner name: MIDCAP FINANCIAL SBIC, LP, MARYLAND Free format text: SECURITY INTEREST;ASSIGNOR:ISTO TECHNOLOGIES, INC.;REEL/FRAME:034805/0001 Effective date: 20141222 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ISTO TECHNOLOGIES, INC., MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FUNDING XVIII TRUST, AS SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL SBIC, LP;REEL/FRAME:038903/0645 Effective date: 20160603 |